A UK consensus on the management of the bladder in multiple sclerosis

Postgraduate Medical Journal

Volumn 85, Issue 1008, 2009, Pages 552-559

  Fowler, C J ^a   Panicker, J N ^a   Drake, M ^b   Harris, C ^c   Harrison, S C W ^d   Kirby, M ^e   Lucas, M ^f   Macleod, N ^g   Mangnall, J ^h   North, A ⁱ   Porter, B ^a   Reid, S ^j   Russell, N ⁱ   Watkiss, K ^k   Wells, M ^l  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c BORDERS GENERAL HOSPITAL   (United Kingdom)

^d PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^f MORRISTON HOSPITAL   (United Kingdom)

^g WESTERN GENERAL HOSPITAL   (United Kingdom)

^h Doncaster Gate Hospital   (United Kingdom)

ⁱ MS Trust   (United Kingdom)

^j NORTHERN GENERAL HOSPITAL   (United Kingdom)

^k PRINCESS ROYAL HOSPITAL   (United Kingdom)

^l Integrated Bladder and Bowel Care   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CANNABINOID; CAPSAICIN; CORTICOSTEROID; DARIFENACIN; DESMOPRESSIN; DIURETIC AGENT; FESOTERODINE; LYRINEL XL; MITOXANTRONE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PROPANTHELINE BROMIDE; PROPIVERINE; RESINIFERATOXIN; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

BLADDER CATHETERIZATION; BLADDER DISEASE; BLADDER EMPTYING; BLADDER TRAINING; CLINICAL TRIAL; CONSENSUS; CONSERVATIVE TREATMENT; CREDE; DISEASE COURSE; DISEASE SEVERITY; DRUG ELIMINATION; DRUG HALF LIFE; FLUID INTAKE; HUMAN; LOWER URINARY TRACT SYMPTOM; MICTURITION DISORDER; MULTIPLE SCLEROSIS; NEUROMODULATION; NOCTURIA; OVERACTIVE BLADDER; PATIENT CARE; PELVIC FLOOR MUSCLE TRAINING; PHYSIOTHERAPY; PRACTICE GUIDELINE; RESIDUAL URINE; REVIEW; SACRAL NEUROMODULATION; SOCIOECONOMICS; SUPRAPUBIC VIBRATION; SURGICAL TECHNIQUE; TREATMENT PLANNING; UNITED KINGDOM; URINALYSIS; URINARY TRACT INFECTION; URINE INCONTINENCE; URODYNAMICS;

FEMALE; GREAT BRITAIN; HUMANS; MALE; MULTIPLE SCLEROSIS; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URINARY TRACT INFECTIONS; URODYNAMICS;

EID: 70349845519     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/jnnp.2008.159178     Document Type: Review

References (47)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-1231
2. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006;5:932-936 (Pubitemid 44556546)
3. Robertson N, Compston A. Surveying multiple sclerosis in the United Kingdom. J Neurol Neurosurg Psychiatry 1995;58:2-6.
4. Williams ES, McKeran RO. Prevalence of multiple sclerosis in a south London borough. BMJ (Clin Res Ed) 1986;293:237-239 (Pubitemid 16064221)
5. Swingler RJ, Compston DA. The prevalence of multiple sclerosis in south east Wales. J Neurol Neurosurg Psychiatry 1988;51:1520-1524
6. Phadke JG, Downie AW. Epidemiology of multiple sclerosis in the north-east (Grampian region) of Scotland - an update. J Epidemiol Community Health 1987;41:5-13. (Pubitemid 17017739)
7. Cook SD, Cromarty JI, Tapp W, et al. Declining incidence of multiple sclerosis in the Orkney Islands. Neurology 1985;35:545-551 (Pubitemid 15085074)
8. Marrie RA, Cutter G, Tyry T, et al. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology 2007;68:1971-1978 (Pubitemid 46869700)
9. Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125:952-960 (Pubitemid 34464607)
10. Hemmett L, Holmes J, Barnes M, et al. What drives quality of life in multiple sclerosis? QJM 2004;97:671-676
11. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452-457 (Pubitemid 350308769)
12. Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technol Assess 2001;5:1-69.
13. Fowlis GA, Waters J, Williams G. The cost effectiveness of combined rapid tests (Multistix) in screening for urinary tract infections. J R Soc Med 1994;87:681-682 (Pubitemid 24334656)
14. de Seze M, Ruffion A, Denys P, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007;13:915-928 (Pubitemid 351540864)
15. Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int 2008;102:62-66
16. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs 2002;11:560-565
17. McClurg D, Ashe RG, Marshall K, et al. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 2006;25:337-348 (Pubitemid 44162819)
18. Vahtera T, Haaranen M, Viramo-Koskela AL, et al. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehabil 1997;11:211-219 (Pubitemid 27458526)
19. Logan K, Shaw C, Webber I, et al. Patients' experiences of learning clean intermittent self-catheterization: a qualitative study. J Adv Nurs 2008;62:32-40.
20. O'Riordan JI, Doherty C, Javed M, et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol 1995;153:1114-1116
21. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398
22. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 2003;17:42-47 (Pubitemid 36230979)
23. Abrams P, Agarwal M, Drake M, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int 2008;101:989-994
24. Infection control. Prevention of healthcare-associated infection in primary and community care. London: National Institute for Health and Clinical Excellence, 2003.
25. Multiple sclerosis. Management of multiple sclerosis in primary and secondary care. London: National Institute for Health and Clinical Excellence, 2003.
26. Lekka E, Lee LK. Successful treatment with intradetrusor botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol 2006;50:806-809 (Pubitemid 44349031)
27. Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986;135:966-968
28. Ethans KD, Nance PW, Bard RJ, et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004;27:214-218
29. Amend B, Hennenlotter J, Schafer T, et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased sideeffects. Eur Urol 2008;53:1021-1028
30. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50:317-326 (Pubitemid 44038078)
31. Fader M, Glickman S, Haggar V, et al. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol 2007;177:208-213 (Pubitemid 44879451)
32. Weese DL, Roskamp DA, Leach GE, et al. Intravesical oxybutynin chloride: experience with 42 patients. Urology 1993;41:527-530
33. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196-200. (Pubitemid 40825713)
34. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebocontrolled, double-blind study. Scand J Urol Nephrol 2007;41:335-340 (Pubitemid 47357195)
35. Game X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008;53:613-618 (Pubitemid 351178997)
36. Bosma R, Wynia K, Havlikova E, et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005;112:1-5. (Pubitemid 40827594)
37. Freeman RM, Adekanmi O, Waterfield MR, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised, placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17:636-641 (Pubitemid 44575283)
38. de Seze M, Wiart L, Joseph PA, et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998;17:513-523 (Pubitemid 28462644)
39. Kim JH, Rivas DA, Shenot PJ, et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 2003;26:358-363
40. Reynard JM, Cannon A, Yang Q, et al. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 1998;81:215-218 (Pubitemid 28316454)
41. Barnes MP, Bates D, Cartlidge NE, et al. Hyperbaric oxygen and multiple sclerosis: short-term results of a placebo-controlled, double-blind trial. Lancet 1985;1:297-300. (Pubitemid 15157123)
42. Barnes MP, Bates D, Cartlidge NE, et al. Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial. J Neurol Neurosurg Psychiatry 1987;50:1402-1406 (Pubitemid 17156433)
43. Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 2007;197:96, e91-5.
44. Cappellano F, Bertapelle P, Spinelli M, et al. Quality of life assessment in patients who undergo sacral neuromodulation implantation for urge incontinence: an additional tool for evaluating outcome. J Urol 2001;166:2277-2280 (Pubitemid 33065273)
45. Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, et al. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 2000;164:1476-1480
46. Hess MJ, Hess PE, Sullivan MR, et al. Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord 2008;46:622-626
47. Morton SC, Shekelle PG, Adams JL, et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil 2002;83:129-138 (Pubitemid 34052151)